Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
AGuIX Gadolinium-Based Nanoparticles by NH TherAguix for Glioblastoma Multiforme (GBM): Likelihood of Approval
AGuIX Gadolinium-Based Nanoparticles is under clinical development by NH TherAguix and currently in Phase II for Glioblastoma Multiforme (GBM). According...